RXSIGHT INC (RXST) Stock Price, Quote, News and Overview
NASDAQ:RXST - Nasdaq - US78349D1072 - Common Stock - Currency: USD
RXST Quote, Performance and Key Statistics
7.65
-0.27 (-3.41%)
The current stock price of RXST is 7.65 USD. In the past month the price decreased by -40.19%. In the past year, price decreased by -84.92%.
RXST Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 28.51 | 42.74B | ||
| COO | COOPER COS INC/THE | 17.93 | 13.88B | ||
| SOLV | SOLVENTUM CORP | 12.17 | 12.53B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.84 | 10.12B | ||
| BLCO | BAUSCH + LOMB CORP | 34.38 | 5.11B | ||
| LNTH | LANTHEUS HOLDINGS INC | 10.97 | 5.03B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.08 | 4.99B | ||
| HAE | HAEMONETICS CORP/MASS | 16.65 | 3.66B | ||
| ICUI | ICU MEDICAL INC | 18.48 | 3.18B | ||
| XRAY | DENTSPLY SIRONA INC | 8.36 | 2.80B | ||
| UFPT | UFP TECHNOLOGIES INC | 26.99 | 1.86B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.34B |
Related stock screener links
About RXST
Company Profile
RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. The company is headquartered in Aliso Viejo, California and currently employs 498 full-time employees. The company went IPO on 2021-07-30. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. The company designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.
Company Info
RXSIGHT INC
100 Columbia Street, Suite 120
Aliso Viejo CALIFORNIA US
CEO: Ron Kurtz
Employees: 374
Phone: 19495217822
RXSIGHT INC / RXST FAQ
What is the stock price of RXSIGHT INC today?
The current stock price of RXST is 7.65 USD. The price decreased by -3.41% in the last trading session.
What is the ticker symbol for RXSIGHT INC stock?
The exchange symbol of RXSIGHT INC is RXST and it is listed on the Nasdaq exchange.
On which exchange is RXST stock listed?
RXST stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RXSIGHT INC stock?
17 analysts have analysed RXST and the average price target is 11.86 USD. This implies a price increase of 55% is expected in the next year compared to the current price of 7.65. Check the RXSIGHT INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RXSIGHT INC worth?
RXSIGHT INC (RXST) has a market capitalization of 310.90M USD. This makes RXST a Small Cap stock.
How many employees does RXSIGHT INC have?
RXSIGHT INC (RXST) currently has 374 employees.
What are the support and resistance levels for RXSIGHT INC (RXST) stock?
RXSIGHT INC (RXST) has a resistance level at 7.74. Check the full technical report for a detailed analysis of RXST support and resistance levels.
Is RXSIGHT INC (RXST) expected to grow?
The Revenue of RXSIGHT INC (RXST) is expected to decline by -2.51% in the next year. Check the estimates tab for more information on the RXST EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy RXSIGHT INC (RXST) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RXST, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RXST, evaluating the profitability, health, valuation and growth aspects
- RXSIGHT INC (RXST) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RXSIGHT INC (RXST) Sales and EPS estimates to see what analysts future expectations are.
- RXSIGHT INC (RXST) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RXSIGHT INC (RXST) Insider and Institutional Ownership to learn about the owners and their transactions.
- RXSIGHT INC (RXST) Stock Chart to make your own analysis
- RXSIGHT INC (RXST) Latest news and press-releases to stay up to date.
Does RXSIGHT INC (RXST) stock pay dividends?
RXST does not pay a dividend.
When does RXSIGHT INC (RXST) report earnings?
RXSIGHT INC (RXST) will report earnings on 2025-08-07, after the market close.
What is the Price/Earnings (PE) ratio of RXSIGHT INC (RXST)?
RXSIGHT INC (RXST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).
What is the Short Interest ratio of RXSIGHT INC (RXST) stock?
The outstanding short interest for RXSIGHT INC (RXST) is 12.98% of its float. Check the ownership tab for more information on the RXST short interest.
RXST Technical Analysis
RXST Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RXST. The financial health of RXST is average, but there are quite some concerns on its profitability.
RXST Financial Highlights
Over the last trailing twelve months RXST reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS increased by 44.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.48% | ||
| ROE | -9.5% | ||
| Debt/Equity | 0 |
RXST Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to RXST. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -25.83% and a revenue growth -2.51% for RXST